Panthera is now undertaking Phase II, III and IV vaccine trials on behalf of its pharma and CRO clients across its growing network of sites in the UK.
“We have been approached by several sponsors to run vaccine studies. Our very experienced team has a great deal of expertise in this area and with our increasing number of sites across the UK, we are well positioned to deliver both patients and healthy volunteers, who are at lower risk for COVID-19, for these trials,” CEO Stuart Young said.
Panthera is continuing its planned expansion with an increase in its network of sites across the UK and discussions with partners on international expansion, and specialized services in neurology, oncology and NASH are in development.
The safety of clinical trial patients and staff is paramount and Panthera is working with its pharma and CRO clients to assess each trial to see if it needs to be suspended, delayed or if it can be continued in a way that is safe both for the clinicians and participants. Panthera is working with sponsors who need to press ahead with trials, particularly those trials involving patients in high-risk categories. Panthera already has remote patient visit protocols in place including using phone or video links. These links are also being used for monitoring and site inspections.